Edition:
United States

Bellicum Pharmaceuticals Inc (BLCM.OQ)

BLCM.OQ on NASDAQ Stock Exchange Global Market

7.52USD
20 Apr 2018
Change (% chg)

$-0.02 (-0.27%)
Prev Close
$7.54
Open
$7.54
Day's High
$7.65
Day's Low
$7.32
Volume
242,622
Avg. Vol
238,620
52-wk High
$14.45
52-wk Low
$5.02

Latest Key Developments (Source: Significant Developments)

Bellicum Pharmaceuticals Announces Proposed Public Offering Of Common Stock
Monday, 16 Apr 2018 04:42pm EDT 

April 16 (Reuters) - Bellicum Pharmaceuticals Inc ::BELLICUM PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.SAYS OFFERING 7.00 MILLION COMMON SHARES.  Full Article

Bellicum Pharmaceuticals Reports Qtrly Loss Per Share $0.66
Tuesday, 13 Mar 2018 04:01pm EDT 

March 13 (Reuters) - Bellicum Pharmaceuticals Inc ::BELLICUM PHARMACEUTICALS PROVIDES OPERATIONAL UPDATE AND REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2017.‍REMAINS ON TRACK TO FILE EUROPEAN MARKETING AUTHORIZATION APPLICATIONS FOR BPX-501 AND RIMIDUCID IN 2019​.QTRLY LOSS PER SHARE $0.66‍​.Q4 EARNINGS PER SHARE VIEW $-0.70 -- THOMSON REUTERS I/B/E/S.  Full Article

Bellicum Announces Interim Results Showing Low Rates Of Cancer Recurrence In Pediatric AML Patients Treated With BPX-501
Tuesday, 13 Mar 2018 07:00am EDT 

March 13 (Reuters) - Bellicum Pharmaceuticals Inc ::BELLICUM ANNOUNCES INTERIM RESULTS SHOWING LOW RATES OF CANCER RECURRENCE IN PEDIATRIC AML PATIENTS TREATED WITH BPX-501.BELLICUM PHARMA - WORKING WITH INVESTIGATORS & U.S. FDA TO DEVELOP PROTOCOL FOR POTENTIAL U.S. REGISTRATION STUDY IN PEDIATRIC PATIENTS.BELLICUM PHARMA - EXPECTS TO INITIATE POTENTIAL U.S. REGISTRATION STUDY IN PEDIATRIC PATIENTS BY END OF 2018.BELLICUM PHARMA - FROM BP-004 STUDY, CO REPORTED HIGH RATES OF DISEASE-FREE SURVIVAL & OVERALL SURVIVAL IN PEDIATRIC PATIENTS WITH PID.  Full Article

Bellicum Pharma Says Effective Feb 20, Board Approved Increase In Size Of Board To 8 Members
Friday, 23 Feb 2018 04:24pm EST 

Feb 23 (Reuters) - Bellicum Pharmaceuticals Inc ::BELLICUM PHARMA SAYS EFFECTIVE FEB 20, BOARD APPROVED INCREASE IN SIZE OF BOARD TO 8 MEMBERS - SEC FILING.  Full Article

Bellicum Announces Update On Clinical Hold Of U.S. BPX-501 Studies
Friday, 23 Feb 2018 07:00am EST 

Feb 23 (Reuters) - Bellicum Pharmaceuticals Inc ::BELLICUM ANNOUNCES UPDATE ON CLINICAL HOLD OF U.S. BPX-501 STUDIES.BELLICUM - RECEIVED NOTIFICATION FROM FDA OUTLINING CRITERIA REQUIRED FOR LIFTING CLINICAL HOLD ON U.S. STUDIES OF BPX-501.BELLICUM PHARMACEUTICALS INC - CLINICAL HOLD DOES NOT AFFECT COMPANY'S BP-004 REGISTRATION TRIAL IN EUROPE.BELLICUM - PLANS TO IMPLEMENT REVISIONS TO U.S. STUDY PROTOCOLS, ADDITION OF MORE COMPREHENSIVE MONITORING, MANAGEMENT OF NEUROTOXICITY FOR BPX-501.  Full Article

Bellicum reports qtrly earnings per share loss‍ $0.71​
Tuesday, 7 Nov 2017 04:05pm EST 

Nov 7 (Reuters) - Bellicum Pharmaceuticals Inc ::Bellicum reports third quarter 2017 financial results.Bellicum Pharmaceuticals Inc qtrly earnings per share loss‍ $0.71​.Q3 earnings per share view $-0.74 -- Thomson Reuters I/B/E/S.  Full Article

Bellicum Pharmaceuticals enters a cancer research grant contract with cancer prevention and research institute of Texas
Tuesday, 15 Aug 2017 04:46pm EDT 

Aug 15 (Reuters) - Bellicum Pharmaceuticals Inc ::Bellicum Pharmaceuticals says ‍on Aug. 9, entered a cancer research grant contract with cancer prevention and research institute of Texas .Bellicum Pharmaceuticals- under agreement CPRIT awarded grant of about $16.9 million to bellicum to fund research of a cancer therapy involving BPX-501​.Bellicum Pharmaceuticals Inc - Bellicum and CPRIT will retain joint ownership over any intellectual property developed under agreement.Bellicum Pharmaceuticals Inc - agreement will expire on February 29, 2020.  Full Article

Bellicum Pharmaceuticals qtrly loss per share $0.74
Tuesday, 8 Aug 2017 04:05pm EDT 

Aug 8 (Reuters) - Bellicum Pharmaceuticals Inc :Bellicum pharmaceuticals reports second quarter 2017 financial results and provides corporate update.Bellicum pharmaceuticals inc qtrly loss per share $0.74.Bellicum pharmaceuticals inc says enrollment in pivotal eu bp-004 trial remains on track for completion by end of 2017.Bellicum pharmaceuticals -expects to initiate observational trial in pediatric patients receiving transplants from matched unrelated donors without bpx-501 in q3.  Full Article

Bellicum Pharmaceuticals files for mixed shelf offering of upto $150 mln
Wednesday, 28 Jun 2017 05:26pm EDT 

June 28 (Reuters) - Bellicum Pharmaceuticals Inc -:Bellicum Pharmaceuticals Inc files for mixed shelf offering of upto $150 million - sec filing.  Full Article

Bellicum Pharmaceuticals files prospectus relating to disposition of up to about 5 million shares
Wednesday, 28 Jun 2017 04:58pm EDT 

June 28 (Reuters) - Bellicum Pharmaceuticals Inc :Bellicum Pharmaceuticals files prospectus relating to disposition of up to about 5 million shares of co's common stock held by the selling stockholders.Bellicum Pharmaceuticals says it is not selling any shares of common stock and will not receive any of the proceeds from sale of shares by selling stockholders.  Full Article